Section He-P 4035.12 - Mobile Medical Service Administrative Requirements(a) DHHS/RHS shall license mobile medical services and/or clients of such services, limited to the following services:(1) Uptake, dilution and excretion;(2) Imaging and localization;(3) Sealed sources in diagnosis; and(4) Certain in-vitro clinical or laboratory testing.(b) The client of the mobile medical service shall be licensed by DHHS/RHS if the client receives or possesses byproduct material to be used by a mobile medical service.(c) Mobile medical service licensees shall obtain a letter signed by the management of each client for which services are rendered that permits the use of byproduct material at the client's address and clearly delineates the authority and responsibility of the licensee and the client. Each letter shall be retained 3 years after the last provision of service.(d) If the client is licensed, the letter shall document procedures for notification, receipt, storage and documentation of transfer of byproduct material delivered to the client's location for use by the mobile medical service.(e) A mobile medical service shall not have byproduct material delivered directly from the manufacturer or the distributor to the client's address of use, unless the client has a license to receive and possess that byproduct material.(f) Byproduct material delivered to the client's address of use shall be received and handled in conformance with the client's license. The mobile medical service shall: (1) Check instruments used to measure the activity of unsealed byproduct material for proper function before medical use at each client's address or on each day of use, whichever is more frequent. At a minimum, the check for proper function shall include a constancy check;(2) Check survey instruments for proper operation with a dedicated check source before use at each client's address; and(3) Before leaving a client's address, survey all areas of use to ensure compliance with the requirements in He-P 4022.(g) A mobile medical service shall inform a responsible individual, such as a representative of management, a registered nurse in charge of the patient, or the registered nurse in charge of the nursing unit, who is on site at each client's address of use at the time that radiopharmaceuticals are being administered.N.H. Admin. Code § He-P 4035.12
(See Revision Note at part heading for He-P 4035) #6942, eff 2-1-99; ss by #8800, INTERIM, eff 2-1-07, EXPIRED: 7-31-07
New. #8959, eff 8-7-07
Amended by Volume XXXV, Number 32 Filed August 13, 2015, Proposed by #10897, Effective 7/22/2015, Expires1/18/2016.Amended by Volume XXXVI Number 01, Filed January 7, 2016, Proposed by #11011, Effective 1/15/2016, Expires 1/15/2026.Amended by Volume XL Number 24, Filed June 11, 2020, Proposed by #13048, Effective 6/2/2020, Expires 6/2/2030.Amended by Volume XLII Number 45, Filed November 10, 2022, Proposed by #13473, Effective 10/25/2022, Expires 10/25/2032